

# Emergence of the first manic episode in recovered COVID-19 patients: A case series from Egypt

Hayam M. Elgohary

College of Medicine, Zagazig University

Mohammad G. Sehlo

College of Medicine, Zagazig University

Usama M. Youssef

College of Medicine, Zagazig University

Mohamed Abdelghani (✉ [abdelghanim@alumni.vcu.edu](mailto:abdelghanim@alumni.vcu.edu))

College of Medicine, Zagazig University <https://orcid.org/0000-0002-1245-6289>

---

## Case Report

**Keywords:** COVID-19, manic episode, case series

**Posted Date:** October 12th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-964024/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

## Objective

In December 2019, the novel coronavirus (COVID-19) infection was first reported in Wuhan city, China, which had rapidly spread as a global pandemic. This infection was commonly presented by respiratory and /or gastrointestinal symptoms. However, it is still unclear whether COVID-19 infection could be associated with central nervous system (CNS) damage which would result in development of neuropsychiatric symptoms.

## Method

A total of five cases of suddenly emerged manic episodes during the pandemic of COVID-19 were extensively described. We presented the symptoms and described the diagnosis, clinical course, and treatment of each case.

## Results

All patients had positive findings of ribonucleic acid (RNA) tests for COVID-19 in specimens of their sputum. The patients later developed manic symptoms during and after the recovering period of their illness.

## Conclusions

The case series of newly emerged manic symptoms associated with COVID-19 infection highlights the essential need for evaluation of mental health status and would contribute to our understanding of the potential risk of CNS affection by COVID-19 infection. The limited number of cases would limit the generalizability of association. Future research should investigate the behavioral changes accompanying and following COVID-19 infection.

## Introduction

Since December 2019, the world's attention was attracted to Wuhan city, the capital of Hubei Province, China, due to an outbreak of the COVID-19 virus infection. As a result of the human-to-human transmission, there were rapidly increasing numbers of established cases caused by human-to-human transmission, with a tremendous rise in deaths not only in China but also worldwide. In January 2020, the World Health Organization (WHO) had declared that the COVID-19 outbreak was a public health emergency of global concern.<sup>1</sup> The clinical manifestations of patients with COVID-19 infection varied from asymptomatic to acute flu-like symptoms as cough, fever, shortness of breath, which might progress to respiratory distress and even failure, exhaustion, as well as gastrointestinal symptoms such

as nausea, vomiting, and diarrhea. Moreover, cardiac and other organ dysfunctions and superimposed infections were also reported.<sup>2-4</sup>

With the global spread of the COVID-19 outbreak, various studies had documented the deleterious impact of COVID-19 virus infection on the mental wellbeing and quality of life in various populations including COVID-19 patients,<sup>5</sup> healthcare providers,<sup>6</sup> patients with pre-existing chronic diseases,<sup>7</sup> and even the general population.<sup>8</sup> In addition, few studies had documented emerging data stating that there was an association between COVID-19 infection and neuropsychiatric symptoms such as brief psychosis, paranoid symptoms, and delirium.<sup>9-11</sup> However, the pathogenesis of these sequelae was still unclear. The etiology of these symptoms was supposed to be attributed to various factors including brain infection, cerebrovascular hyper-coagulopathy, stress-inducing problems such as treatment interventions, emotional disturbances, unemployment, social isolation, COVID-19-related stigma, or drug-induced (corticosteroids or antiviral medications).<sup>12,13</sup>

Few data were reported about manic episodes which emerged during recovery of COVID-19 infection without previous history or family history of mood disorders. The clinical implication for that work is to encourage prospective studies that are essential to determine the real effect and correlates of COVID-19 infection on precipitating manic symptoms and other mood disorders and to furtherly investigate the psychopathology of COVID-19 infection.

## Case Presentations

### Case 1

On July 20, 2020, a 57-year-old male patient was brought to the psychiatric outpatient clinic in Zagazig University with symptoms of mood elation, hyperactivity, psychomotor agitation, pressured speech, decreased need to sleep (only 2 to 3 hours per night was enough), increased appetite, increased self-esteem, increased pleasurable (sexual) activity and delusion of persecution (claiming that the neighbors wanted to harm him). The patient had no previous or family history of primary mood or psychotic disorders. The patient was a nonsmoker, known asthmatic stabilized on bronchodilators, and denied any history of substance use disorders.

Ten days before the emergence of manic symptoms, the patient reported inability to smell and taste, rhinorrhea, fever 38.8, weight cough, and fatigue. His oxygen saturation was 94%, and his respiratory rate was 16. His chest CT scan showed multiple bilateral consolidation and ground glass patches. Later, the diagnosis of COVID-19 was confirmed by a positive throat swab. The laboratory findings revealed serum ferritin 420.8, D-dimer 0.42, ESR (first hour) 24 negative CRP, normal CBC, normal PT and PTT, normal kidney and liver function except for slightly elevated AST and ALT, and normal abdominal ultrasonography except for mildly enlarged liver displaying slightly coarse echo pattern. The following drugs were prescribed for the patient under the supervision of his chest physician: Paracetamol 500 every 8 hours, bromhexine 5 ml every 8 hours, clarithromycin, 500 mg twice daily, theophylline 150 mg twice

daily and betamethasone one ampule once. Within one week, previous symptoms started to disappear. 3-days later, his family noticed the emergence of the previously reported mood and behavioral changes. Treatment included olanzapine 15 mg at night. After 3 weeks of treatment, the patient showed gradual and marked responses especially mood, sleep, and speech symptoms, and was advised to continue the prescribed drug.

## **Case 2**

On July 24, 2020, 69 years old female patient came with her family to the outpatient clinic in Zagazig University presented with symptoms of being talkative, irritable, energetic, and verbally aggressive. The family reported insomnia and early waking, increased appetite especially for pastries, increased pleasurable activity (wearing and buying gold pieces) delusion of persecution (claimed that others tried to hurt her).

The previous symptoms developed two weeks after the patient's complaints of nausea and vomiting, dry cough, fever 38.9, headache, and fatigue. She sought medical treatment at the isolation hospital of her region for 7 days and continued her protocol of treatment at home. The diagnosis of COVID-19 infection was confirmed by a positive throat swap. The advised protocol prescribed for her was Paracetamol 1000 mg every 8 hours, Ceftriaxone 1000 mg ampule for 5 days, Azithromycin 500 mg once daily for 6 days, Levodropropizine 5ml every 8 hours, Ivermectin 6 mg 4 tablets once repeated after 3 days, Enoxaparin sodium 4000 IU, Lactoferrin 100 mg sachet twice daily, and Vitamin C 500 mg capsule twice daily. The patient improved within 1 week of treatment. The laboratory finding during the time of admission revealed high blood sugar 610 mg/dl (discovered for the first time). Other investigations showed moderate leukocytosis 17.81 and neutrophilia 92.5. Her CT brain showed nonspecific age-related brain atrophy. The patient had no history of medical illness except for hypertension 8 years ago controlled on amlodipine 5 mg, hydrochlorothiazide 12.5 mg, Olmesartan 20 mg. She has no psychiatric history or family history of any mental illness or substance abuse.

When she came to the psychiatric clinic, we prescribed risperidone 2 mg which was gradually increased to be 4 mg at night. She started to improve after 4 days of the last dose and completely recovered within 2 weeks of treatment. Psychiatric follow-up during the following weeks was reassuring. The patient showed a stabilized mood and became calm with normal sleep, speech, and appetite continuing the same prescribed drug.

## **Case 3**

On June 4, 2021, a 35-year-old female patient came with her husband to the emergency room in a general hospital after the death of her father with COVID-19. She claimed symptoms of depressed mood, insomnia, and tingling in both hands. A general practitioner prescribed her midazolam 5 mg ampoule STAT, and she was discharged as she became somewhat quiet. Two days later, she gradually became talkative, weeping most of the time, then her mood was switched to be irritable and in a loud voice refusing anyone to interrupt her. Later, the husband noticed her decreased sleep hours with early

awakening and hyperactivity, as well as engagement in unnecessary pleasurable activities (excessive shopping). She accused her mother-in-law that she was making black magic for her husband, and neighbors were spying on her social media accounts. One week later, her husband took her to the same hospital where the GP gave her another midazolam 5 mg amp and consulted a psychiatrist who prescribed Haloperidol 5 mg IM twice daily, Biperiden 2 mg twice daily, and Olanzapine 10 mg at night. She became quiet and sedated with good vital signs. The patient had no history of chronic medical illness, primary mood or psychotic disorders, or substance use disorders.

Her husband informed that three weeks before the former symptoms, the patient complained of flu-like symptoms, cough, fever, generalized body ache, headache, and fatigue. These symptoms started 2 days after she visited her deceased father who was infected with the corona virus. She sought medical treatment with a pulmonologist who requested CT chest revealing multiple pneumonic patches. Her labs revealed elevated CRP and serum ferritin, and Oxygen saturation was 88. The diagnosis of COVID-19 infection was confirmed by a positive throat swap. Medications given included Ceftriaxone 1 gm ampoule once daily, dexamethasone ampoule twice daily for 5 days, and linezolid 600 mg daily for 5 days. She continued her protocol of treatment at home and started to be improved one week after treatment onset.

#### **Case 4**

On June 13, 2021, a 34-year-old female patient came with her mother to a psychiatric clinic suffering from an insidious course of symptoms of irritable mood, insomnia, hyperactivity and talkativeness, and psychomotor agitation. Later, she started screaming and shouting, insulting her family members with obscene words, and spitting on them, and producing sounds like goats. On their way to the clinic, her family forcibly prevented her from standing in front of a running car. The patient had no history of chronic medical illness, primary mood or psychotic disorders, or substance use disorders. After the psychiatric interview, the patient had prescribed olanzapine 20 mg once daily at night, sodium valproate 500 mg three times daily, haloperidol 5 mg IM twice daily and biperiden 2 mg twice daily.

Four weeks before the symptoms, the patient complained of cough, fever, generalized body ache, and fatigue. She sought medical treatment with a pulmonologist who requested CT chest showing mild pneumonic patches, and labs revealing elevated CRP and serum ferritin, and lymphopenia. The diagnosis of COVID-19 infection was confirmed later by a positive throat swap. She received linezolid 600 mg daily for 5 days, four tablets Ivermectin 6 mg once daily for 4 consecutive days, and paracetamol 500 mg 4 times daily with home isolation. The patient's condition started to improve after 5 days of treatment. After three weeks of recovery of Covid-19 symptoms, she started to gradually develop psychiatric symptoms.

#### **Case 5**

On May 24, 2021, a 47-year-old male patient came alone to a psychiatrist complaining of symptoms of depressed mood, lack of interest, chest tightness, unexplained weeping, lack of concentration, fatigue, and suicidal thoughts which developed over two weeks. Later, the patient neglected his work and became

socially withdrawn. CT brain was performed, which looked normal. The depressive symptoms persisted for the next four months despite prescribing venlafaxine 75 mg for one month then 150 mg for 3 months. After revising the patient's psychiatric condition, it was documented that the patient was diagnosed one year earlier with bipolar disorder, manic episode by another psychiatrist when he had symptoms of elated mood, insomnia, talkativeness, hyperactivity, spending a lot of money on non-useful goods and grandiosity thoughts. The prescribed medications were olanzapine 10 mg once daily at night and sodium valproate 1000 mg twice daily. Manic symptoms disappeared gradually after one month of psychotropic medications. Therefore, this patient was eventually diagnosed with bipolar I disorder, recurrent, current episode depressive, and prescribed Olanzapine/Fluoxetine combination 6/25 mg once daily at night.

However, the patient's family reported that the manic symptoms developed three weeks after symptoms of sore throat, mild cough, and anosmia. He sought medical treatment with an internist who requested CT chest showing mild pneumonic patches, and labs revealing elevated CRP and serum ferritin, and leukopenia. The diagnosis of COVID-19 infection was confirmed later by a positive throat swap. The prescribed medications included doxycycline 200 mg on the first day of the course, followed by a maintenance dose of 100 mg regularly for 7-10 days, three tablets of Ivermectin 6 mg once daily for 4 consecutive days and paracetamol 500 mg 4 times daily, with home isolation. The patient improved within 7 days of treatment and stopped his treatment.

## Discussion

In this study, we reported five cases presented with manic episodes shortly after recovery from infection with SARS-CoV-2. These cases had no history of primary mood or psychotic disorders, or substance use disorders. It was reported that depression and anxiety were the most common detected psychiatric symptoms in patients infected with SARS-CoV-2,<sup>5</sup> and this was logic, mostly due to fear from infection and socio-cultural burden associated with COVID-19 infection. A meta-analysis of twelve large studies reported that the pooled prevalence of depression in the general population during the COVID-19 outbreak is 25%.<sup>14</sup> Other studies reported that the prevalence of anxiety during the COVID-19 period ranged from 18–45%.<sup>15,16</sup> The explanation suggested in most of these studies was that excessive exposure to social media news would be associated with higher levels of anxiety and depression.<sup>17,18</sup> Social media would lead to a false fear reaction with ("fake news") during the spread of the disease, rather than real risk.<sup>19</sup> In addition, socio-economic factors such as unemployment, economic burden, and lack of social support might also be considered as contributing factors to the higher rates of emotional instability.<sup>15,17,20</sup>

However, the condition is different when speaking about the development of manic symptoms. It would be rare to report cases of bipolar I disorder or acute psychosis in patients with COVID-19 infection without a past or family history of a psychiatric illness, as these disorders have a strong biological base. To our knowledge, there was only a single case report for a SARS-CoV-2 infected patient who presented with manic-like symptoms.<sup>21</sup> Surprisingly, we reported a total of five cases of typical manic episodes in patients recently recovered from COVID-19 infection without past or family history of primary mood or

psychotic disorders, or substance use disorders, which would be considered one of the very few reports about manic symptoms in patients infected with SARS-CoV-2.

The explanation of the development of concurrent manic symptoms would be related to biological changes that occurred in the brain of SARS-CoV-2 infected patients referring to the ferocious nature of this infection. This would happen owing to the direct effect of the virus on the CNS. In line with this potential, a case of meningitis/encephalitis in a SARS-CoV-2 infected patient was reported.<sup>22</sup> Besides, these brain changes would be attributed to the virus-induced neuroinflammation with the production of high amounts of pro-inflammatory mediators including chemokines in the affected patients, with activation of T-helper-1 (Th1) cell responses.<sup>3</sup> Previous studies found that inflammation-associated immune activation with the release of inflammatory factors was postulated as one of the mechanisms that could lead to the pathogenesis of bipolar disorder.<sup>23,24</sup>

In conclusion, this case series of COVID-19 patients with newly emerged manic episodes highlighted the high possibility of an association between COVID-19 infection and a wide array of psychiatric illnesses and raised the importance of thorough and accurate evaluation of mental health status in those patients for early discovery and management of any mental illness in those patients.

## **Declarations**

### **Contributions**

CMS wrote the draft of the introduction and discussion of the manuscript, while JRK and AM wrote the draft of the case presentation, while participating in clinical care and clinical data extraction for the case. CMS, JRK, AM and BRK reviewed the literature and participated in data interpretation. BRK oversaw the clinical care of the patient. All authors contributed to the final writing, analysis and revising of the article, gave approval for the final version to be published and agree to be accountable for all aspects of the work.

### **Funding**

The authors have not declared a specific grant from any funding agency in the public, commercial or not-for-profit sectors.

### **Acknowledgments**

The authors would like to thank all COVID-19 survivors who accepted to participate in this study.

### **Declaration of conflicting interests**

None declared.

### **Ethical considerations**

The authors obtained an informed written consent from all study participants for participation. All procedures were conducted within the ethical guidelines as outlined in the Declaration of Helsinki and its later amendments.

## References

1. World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020;
2. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. May 1 2020;130(5):2620–2629. doi:10.1172/jci137244
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020/02/15/ 2020;395(10223):497-506. doi:https://doi.org/10.1016/S0140-6736(20)30183-5
4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
5. Abdelghani M, Hassan MS, Alsadik ME, Abdelmoaty AA, Said A, Atwa SA. Post-traumatic stress symptoms among an Egyptian sample of post-remission COVID-19 survivors: prevalence and sociodemographic and clinical correlates. © The Author(s) 2021.; 2021. vol. 1.
6. Abdelghani M, Mahdy R, El-Gohari H. Health anxiety to COVID-19 virus infection and its relationship to quality of life in a sample of health care workers in Egypt: a cross-sectional study. *Archives of Psychiatry and Psychotherapy*. 2021;23(1):19–28.
7. Abdelghani M, Hamed MG, Said A, Fouad E. Evaluation of perceived fears of COVID-19 virus infection and its relationship to health-related quality of life among patients with diabetes mellitus in Egypt during pandemic: a developing country single-center study. *Diabetol Int*. May 12 2021:1–9. doi:10.1007/s13340-021-00511-8
8. Aljemaiah AI, Osman M, Alharbi S, et al. Fear at the time of the COVID-19 pandemic: validation of the Arabic version of the Four-Dimensional Symptom Questionnaire among Saudi-based respondents. *BJPsych Open*. Jan 12 2021;7(1):e33. doi:10.1192/bjo.2020.166
9. Ferrando SJ, Klepacz L, Lynch S, et al. COVID-19 Psychosis: A Potential New Neuropsychiatric Condition Triggered by Novel Coronavirus Infection and the Inflammatory Response? *Psychosomatics*. Sep-Oct 2020;61(5):551–555. doi:10.1016/j.psym.2020.05.012
10. Smith CM, Komisar JR, Mourad A, Kincaid BR. COVID-19-associated brief psychotic disorder. *BMJ Case Reports*. 2020;13(8):e236940. doi:10.1136/bcr-2020-236940
11. He Y, Yu R, Ren J. The Correlation between Psychiatric Disorders and COVID-19: A Narrative Review. *Psychiatr Danub*. Spring 2021;33(1):76–85. doi:10.24869/psyd.2021.76
12. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *Jama*. May



- 26 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
13. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. Mar 28 2020;395(10229):1054–1062. doi:10.1016/s0140-6736(20)30566-3
  14. Bueno-Notivol J, Gracia-García P, Olaya B, Lasheras I, López-Antón R, Santabárbara J. Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies. *Int J Clin Health Psychol*. Jan-Apr 2021;21(1):100196. doi:10.1016/j.ijchp.2020.07.007
  15. Mazza C, Ricci E, Biondi S, et al. A Nationwide Survey of Psychological Distress among Italian People during the COVID-19 Pandemic: Immediate Psychological Responses and Associated Factors. *Int J Environ Res Public Health*. May 2 2020;17(9)doi:10.3390/ijerph17093165
  16. Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. *Int J Soc Psychiatry*. Aug 2020;66(5):504–511. doi:10.1177/0020764020927051
  17. Ni MY, Yang L, Leung CMC, et al. Mental Health, Risk Factors, and Social Media Use During the COVID-19 Epidemic and Cordon Sanitaire Among the Community and Health Professionals in Wuhan, China: Cross-Sectional Survey. *JMIR Ment Health*. May 12 2020;7(5):e19009. doi:10.2196/19009
  18. Gao J, Zheng P, Jia Y, et al. Mental health problems and social media exposure during COVID-19 outbreak. *PloS one*. 2020;15(4):e0231924-e0231924. doi:10.1371/journal.pone.0231924
  19. Sommariva S, Vamos C, Mantzaris A, Đào LU-L, Martinez Tyson D. Spreading the (Fake) News: Exploring Health Messages on Social Media and the Implications for Health Professionals Using a Case Study. *American Journal of Health Education*. 2018 /07/04 2018;49(4):246-255. doi:10.1080/19325037.2018.1473178
  20. Lei L, Huang X, Zhang S, Yang J, Yang L, Xu M. Comparison of Prevalence and Associated Factors of Anxiety and Depression Among People Affected by versus People Unaffected by Quarantine During the COVID-19 Epidemic in Southwestern China. *Medical science monitor: international medical journal of experimental and clinical research*. 2020;26:e924609-e924609. doi:10.12659/MSM.924609
  21. Lu S, Wei N, Jiang J, et al. First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder. *Journal of affective disorders*. 2020;277:337–340. doi:10.1016/j.jad.2020.08.031
  22. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis*. May 2020;94:55–58. doi:10.1016/j.ijid.2020.03.062
  23. Réus GZ, Fries GR, Stertz L, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. *Neuroscience*. Aug 6 2015;300:141–54. doi:10.1016/j.neuroscience.2015.05.018

24. Mazza MG, Tringali AGM, Rossetti A, Botti RE, Clerici M. Cross-sectional study of neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratios in mood disorders. *Gen Hosp Psychiatry*. May-Jun 2019;58:7–12. doi:10.1016/j.genhosppsy.2019.02.003